Diazamed solves a critical medical problem with new anti-fouling materials. It maximizes its value by selling FDA-approved devices to major medtech companies.
Diazamed solves a critical medical problem, fouling of implanted and inserted catheters. Using a mixed-in catalyst, we prevent protein and thrombus attachment, providing solutions where only ineffective fixes have existed. We eliminate the side effects, cost and common failures of coatings in use today. Our innovative business model lets us capture the technology’s full value in contrast to the traditional coating company business model.